Abstract
When attacked by HIV, the immune system counteracts infection with elicitation of HIV-specific antibodies and cytotoxic T lymphocytes. In most cases however, these defenses are unable to resolve HIV infection, which progresses, if left untreated, ravaging the immune system and leading to AIDS and, eventually, to death. Nonetheless, there are additional components of the immune system, from both the innate and the adaptive components, that are associated with improved clinical status and, in some cases, even with protection from infection. Two distinct families of such factors have been studied in depth: chemokines and β-defensins. CCR5 chemokines, which are involved in adaptive immunity, are molecules produced by lymphocytes, and thus are likely to play a role in controlling HIV systemically. β- defensins are instead produced by epithelial cells, and thus are important in controlling infection at mucosal sites. Both of these families of molecules, therefore, are involved in crucial battlegrounds for fighting HIV infection. Here, we review the evidence that argues for their importance in AIDS pathogenesis and in preventive and therapeutic approaches to combat HIV infection. I wish to dedicate this work to my parents,Maria Teresa Ghiglieno and Giovanni Alfredo Garzino
Keywords: AIDS, HIV, CCR5, β-Defensins, RANTES, MIP-1α, MIP-β, MDC
Current Pharmaceutical Design
Title: Chemokines and Defensins as HIV Suppressive Factors: An Evolving Story
Volume: 13 Issue: 2
Author(s): Alfredo Garzino-Demo
Affiliation:
Keywords: AIDS, HIV, CCR5, β-Defensins, RANTES, MIP-1α, MIP-β, MDC
Abstract: When attacked by HIV, the immune system counteracts infection with elicitation of HIV-specific antibodies and cytotoxic T lymphocytes. In most cases however, these defenses are unable to resolve HIV infection, which progresses, if left untreated, ravaging the immune system and leading to AIDS and, eventually, to death. Nonetheless, there are additional components of the immune system, from both the innate and the adaptive components, that are associated with improved clinical status and, in some cases, even with protection from infection. Two distinct families of such factors have been studied in depth: chemokines and β-defensins. CCR5 chemokines, which are involved in adaptive immunity, are molecules produced by lymphocytes, and thus are likely to play a role in controlling HIV systemically. β- defensins are instead produced by epithelial cells, and thus are important in controlling infection at mucosal sites. Both of these families of molecules, therefore, are involved in crucial battlegrounds for fighting HIV infection. Here, we review the evidence that argues for their importance in AIDS pathogenesis and in preventive and therapeutic approaches to combat HIV infection. I wish to dedicate this work to my parents,Maria Teresa Ghiglieno and Giovanni Alfredo Garzino
Export Options
About this article
Cite this article as:
Garzino-Demo Alfredo, Chemokines and Defensins as HIV Suppressive Factors: An Evolving Story, Current Pharmaceutical Design 2007; 13 (2) . https://dx.doi.org/10.2174/138161207779313696
DOI https://dx.doi.org/10.2174/138161207779313696 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Current Medicinal Chemistry Biological Therapies For Inflammatory Bowel Disease: Research DrivesClinics
Mini-Reviews in Medicinal Chemistry Bone Marrow Reconstitution as a Relevant Model of Genetically Programmed Leukemia
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis
Current Pharmaceutical Design Nanotechnology on Duty in Medical Applications
Current Pharmaceutical Biotechnology The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry Animal Models to Investigate Pathomechanisms and Evaluate Novel Treatments for Autoimmune Bullous Dermatoses
Current Pharmaceutical Design Beneficial Effect of Peptides from Microalgae on Anticancer
Current Protein & Peptide Science Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design Therapeutic Vaccines for Cervical Cancer: Dendritic Cell-Based Immunotherapy
Current Pharmaceutical Design Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) The Therapeutic Potential of Cell-Internalizing Aptamers
Current Topics in Medicinal Chemistry Taming Oncogenic Signaling at Protein Interfaces: Challenges and Opportunities
Current Topics in Medicinal Chemistry Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy
Current Cancer Drug Targets Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets Second Generation Adeno-Associated Virus Type 2-based Gene Therapy Systems with the Potential for Preferential Integration into AAVS1
Current Gene Therapy Telomerase as Drug and Drug Target for the Treatment of Thyroid Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Review of Clinic Trials: Agents Targeting c-Met
Reviews on Recent Clinical Trials Immunotherapy for Prostate Cancer
Current Pharmaceutical Design Titanocene Y - Transport and Targeting of an Anticancer Drug Candidate
Letters in Drug Design & Discovery